Indivior Pharmaceuticals Inc (NASDAQ:INDV) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Indivior Pharmaceuticals Q1 2026 Financial Results Conference Call and Webcast.
Indivior Pharmaceuticals Inc. (INDV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 0 | $0 | 0% | |
| 2. | Alta Fundamental Advisers Jeremy Carton And Gilbert Li | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.09 | 8 | $248.68 | 5,724 | 2026-03-13 | Filing | |
| $31.87 | 940 | $29,953.10 | 5,582 | 2026-03-06 | Filing | |
| $32.56 | 31 | $1,009.36 | 5,716 | 2026-03-09 | Filing | |
| $35.39 | 775 | $27,429.27 | 1,963 | 2026-01-05 | Filing | |
| $35.39 | 775 | $27,429.27 | 5,802 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 42,626 | $1,299,240 | 0.01% | |
| 2. | 288 | $9,815 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
Billionaire Howard Marks' 10 Stock Picks with Huge Upside Potential
Howard Marks, the billionaire chief of Oaktree Capital Management, recently appeared on news platform CNBC to outline a measured perspective on the current state of private credit, market valuations, ...
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Q4 2025 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to Indivior Pharmaceuticals Inc's fourth quarter and full year 2025 results conference call and webcast.
Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance
Indivior PLC (NASDAQ:INDV) is one of the best performing pharma stocks in 2025.
10 Best Performing Pharma Stocks in 2025
On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook...
Indivior PLC (NASDAQ:INDV) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Indivior PLC Q3 Results 2025 Webcast and Conference Call.
Indivior (INDV) Jumps to New High on Earnings Blowout, Optimistic Outlook
Indivior climbed for a third straight day on Thursday to reach a new all-time high, as investors cheered a stellar earnings performance and a highly optimistic business outlook for the rest of the year...
Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M
Indivior PLC (NASDAQ:INDV) is a pharmaceutical company specializing in treatments for opioid use disorder (OUD), with its core products SUBLOCADE, a once-monthly buprenorphine injection, and SUBOXONE ...
12 Best Performing Healthcare Stocks to Buy Right Now
Spending on healthcare in the US is predicted to hit $5.3 trillion this year, making it one of the largest in the world.
Indivior Plc (INDV) Jumps 22.8% on Impressive Earnings, Outlook
In an updated report last week, Indivior PLC (NASDAQ:INDV) said that it swung to a net income of $18 million in the second quarter of the year from a $97 million net loss in the same period last year...